FDA Brief

Warning letters Drugs

FDA warning letter to

Secret of the Islands

High riskIssued Aug 10, 2021Posted Aug 11, 2021Center for Drug Evaluation and Research

FDA warned Secret of the Islands that its salt scrub products are unapproved and misbranded drugs because of COVID-19 claims.

What happened

FDA reviewed the company’s website on July 26, 2021, and its Facebook page, which directs consumers to the website to buy products. FDA found various salt scrub products offered for sale with claims that they kill or deactivate the Coronavirus and are doctor-approved anti-bacterial and anti-viral. FDA says these claims make the products unapproved new drugs (drugs FDA has not approved) and misbranded drugs (drugs with false or misleading labeling).

What FDA found

  1. The salt scrub products are unapproved new drugs because the company intends them to prevent or treat COVID-19 without FDA approval.

    Section 505(a) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(a)
  2. The products are misbranded drugs under the FD&C Act.

    Section 502 of the FD&C Act, 21 U.S.C. § 352
  3. Introducing or delivering these products into interstate commerce is prohibited.

    Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The website claims the salt scrub is a doctor-approved anti-bacterial and anti-viral product that kills or deactivates the Coronavirus.

  5. The website says there is a shortage of 12 oz jars due to the Coronavirus, tying the product to COVID-19.

What FDA wants

FDA tells the company to immediately stop selling the products and, within 48 hours, email a description of steps taken, how it will prevent recurrence, and related documents.

Who should pay attention

  • retailers and online marketplaces selling salt scrubs or cosmetics with COVID-19 claims
  • cosmetic and personal-care brands that make antiviral or antibacterial claims
  • companies marketing products during public health emergencies

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk